L3242
The cell line is not validated yet.
SCVIi185-A
General
iPSC Line |
|
| hPSCreg name | SCVIi185-A |
| Cite as: | SCVIi185-A |
| Alternative name(s) |
L3242
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 15th August 2026 |
| User feedback | |
Provider |
|
| Generator | Stanford Cardiovascular Institute (SCVI) |
| Owner | Stanford Cardiovascular Institute (SCVI) |
| Distributors | |
| Derivation country | United States |
External iPSC Databases |
|
| BioSamples | SAMEA123350089 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 30-34 |
| Ethnicity | East Asian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA123350090 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | Access is limited to the study team under IRB #29904; clinical genetic testing results were provided in de-identified form via the referring clinicians at Stanford Neurology. No medical records are released to third parties. |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
| Contact data, institution, or website: | Stanford Cardiovascular Institute, 265 Campus Drive, Stanford, CA 94305, USA; joewu@stanford.edu |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Stanford University Administrative Panel on Human Subjects Research (Institutional Review Board) |
| Approval number | 29904 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Thermo Fisher Scientific — CytoTune™-iPSC 2.0 Sendai Reprogramming Kit (cat. no. A16517) |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
iPSC Derivation
General |
|
| Source cell type |
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Synonyms
|
| Source cell origin |
A fluid that is composed of blood plasma and erythrocytes.
Synonyms
|
| Source cell type (free text) | PBMCs isolated from whole blood by Percoll density-gradient centrifugation |
| Age of donor (at collection) | 30-34 |
| Collected in | 2023 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | Residual Sendai virus genome was assessed by RT-qPCR at passage 19 and was undetectable. Early-passage Sendai-reprogrammed iPSCs served as the positive control, normalised to GAPDH (TaqMan assay Mr04269880_mr). |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Colonies with typical iPSC morphology picked manually 10–15 days post-transduction and expanded feeder-free |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex | |||||||||
| Feeder cells |
No |
|||||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
|||||||||
| O2 Concentration | 21 % | |||||||||
| CO2 Concentration | 5 % | |||||||||
| Medium |
Other medium:
Base medium: StemMACS iPS-Brew XF Basal Medium
Main protein source: Human serum albumin Serum concentration: 0 % Supplements
|
|||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | Unknown |
|||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
Differentiation Potency
In vitro directed differentiation
Morphology
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.